Biswas, S., Srivastava, Y., Falodia, R., Hamadttu, A. (2026). Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.283